Metropolis healthcare Limited has released its business update for the quarter ended March 31, 2026, showcasing strong operational performance with consolidated revenue growth of ~23% on a year-on-year basis. The update, filed under Regulation 30 of SEBI regulations, highlights robust momentum across key business segments and channels.

Strong Revenue Performance Across Segments

The company's consolidated performance for Q4FY26 demonstrates significant growth momentum across multiple business verticals. The ~23% year-on-year revenue growth includes contributions from recent acquisitions including Core Diagnostics, Scientific Pathology, Dr. Ahuja's Pathology & Imaging Center (DAPIC), and Dr. RS Patil's Ambika Pathology Laboratory (Ambika).

Acquisition Integration Shows Positive Results

The company's recent acquisitions are demonstrating successful integration with tangible synergy benefits. Core Diagnostics has shown margin improvement, reaching the high single-digit range in Q4FY26. The acquired entities DAPIC, Scientific, and Ambika continue to deliver margins higher than the company's average, contributing positively to overall profitability.

The strong B2B revenue growth of ~30% was particularly driven by specialty growth and higher B2B contribution from Core Diagnostics, indicating successful cross-selling and market expansion strategies.

Organic Growth Momentum Continues

Excluding recent acquisitions, Metropolis Healthcare's organic business achieved ~14.5% year-on-year revenue growth in Q4FY26. This organic growth was primarily driven by:

• Increased patient volumes
• Higher test volumes
• Improved product mix

The company also reported improved EBITDA margins for the quarter on a year-on-year basis, attributed to operating leverage and efficiency gains across operations.

Wellness and Specialty Segments Drive Growth

The TruHealth wellness segment recorded ~25% growth on a year-on-year basis, while specialty segments achieved ~29% growth during Q4FY26. This performance reflects the company's strategic focus on high-value testing services and preventive healthcare solutions.

The balanced growth across both B2B and B2C channels, supported by volume increases and product mix improvements, demonstrates the company's diversified revenue approach and market penetration capabilities.

Regulatory Compliance and Future Outlook

The business update was filed in accordance with SEBI regulations and the company's Code of Fair Disclosure. The quarterly update is presented on a consolidated basis, with financial results for Q4FY26 subject to audit. A detailed information update will follow once the Board of Directors approves the complete financial results for the quarter.

Metropolis Healthcare Limited has completed the allotment of bonus equity shares on March 23, 2026, issuing 15,54,95,826 new equity shares to eligible shareholders. The bonus issue was executed in a 3:1 ratio, providing three new fully paid-up equity shares for every existing share held by shareholders whose names appeared in the company's records as of March 20, 2026.

Bonus Share Allotment Details

The healthcare diagnostics company allotted the bonus shares with a face value of INR 2/- each as fully paid equity shares. The allotment was made to eligible members whose names appeared in the Register of Members or Register of Beneficial Owners as on the record date of March 20, 2026.

Impact on Share Capital Structure

Following the bonus share allotment, Metropolis Healthcare's capital structure has undergone significant changes. The paid-up share capital has increased substantially from the pre-bonus levels.

Regulatory Compliance

The bonus share allotment was conducted pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company had previously informed the stock exchanges through intimations dated February 04, 2026, March 09, 2026, and March 10, 2026, regarding the bonus issue process.

Stock Exchange Communication

Metropolis Healthcare formally communicated the completion of the bonus share allotment to both BSE Limited (Scrip Code: 542650) and National Stock Exchange of India Ltd. (Scrip Symbol: METROPOLIS) on March 23, 2026. The communication was signed by Kamlesh C Kulkarni, Head – Legal & Secretarial, confirming the successful completion of the corporate action.

The bonus issue represents a significant corporate action for the diagnostic services company, effectively quadrupling the number of shares held by existing shareholders while maintaining their proportionate ownership in the company.